Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist

Journal of Pharmaceutical Sciences

Volumn 94, Issue 12, 2005, Pages 2735-2748

  Chi, Eva Y ^a   Kendrick, Brent S ^b   Carpenter, John F ^c   Randolph, Theodore W ^a  

^a UCB 450   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Aggregate size distribution; Benzyl alcohol; Excipients; Formulation; Growth rate; Nucleation rate; Precipitation; Preservatives; Protein aggregation kinetics

Indexed keywords

BENZYL ALCOHOL; BUFFER; CITRATE SODIUM; CITRIC ACID; EDETIC ACID; EXCIPIENT; HYDROCHLORIC ACID; PRESERVATIVE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; SODIUM HYDROXIDE; SUCROSE;

ARTICLE; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; DRUG FORMULATION; GROWTH RATE; KINETICS; MIXED PRODUCT REMOVAL REACTOR; PARTICLE SIZE; POPULATION BALANCE; POPULATION DENSITY; PRECIPITATION; PROTEIN AGGREGATION; REACTOR; STATISTICAL MODEL; STEADY STATE; SUSPENSION;

EID: 33144466335     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20488     Document Type: Article

References (35)

1. Soto C. 2003. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev Neurosci 4:49-60.
2. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
3. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations-a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carr Syst 10:307-377.
4. Kim JR, Gibson TJ, Murphy RM. 2003. Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides. J Biol Chem 278:40730-40735.
5. Roberts CJ. 2003. Kinetics of irreversible protein aggregation: Analysis of extended Lumry-Eyring models and implications for predicting protein shelf life. J Phys Chem B 107:1194-1207.
6. Roberts CJ, Darrington RT, Whitley MB. 2003. Irreversible aggregation of recombinant bovine Granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J Pharm Sci 92:1095-1111.
7. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12:903-913.
8. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in non-native protein aggregation. Pharm Res 20:1325-1336.
9. Przybycien TM, Bailey JE. 1989. Aggregation kinetics in salt-induced protein precipitation. AIChE J 35:1779-1790.
10. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. 1996. On the nucleation and growth of amyloid beta-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 93:1125-1129.
11. Randolph AD, Larson MA. 1962. Transient and steady state size distributions in continuous mixed suspension crystallizers. AIChE J 8:639-645.
12. Randolph AD. 1965. The mixed suspension, mixed product removal crystallizer as a concept in crystallizer design. AIChE J 11:424-430.
13. Randolph AD, Larson MA. 1988. Theory of particulate processes: Analysis and techniques of continuous crystallization, 2nd edn. San Diego: Academic Press, Inc. 369p.
14. Canning TF, Randolph AD. 1967. Some aspects of crystallization theory: Systems that violate McCabe's delta L law. AIChE J 13:5-10.
15. Abegg CF, Stevens JD, Larson MA. 1968. Crystal size distribution in continuous crystallizers when growth rate is size dependent. AIChE J 14:118-122.
16. Glatz CE. 1992. Chapter 5. Modeling of aggregation-precipitation phenomena. In: Ahern TJ, Manning MC, editors. Stability of protein pharmaceuticals part A: Chemical and physical pathways of protein degradation. New York: Plenum Press, p 215.
17. Nelson CD, Glatz CE. 1985. Primary particle formation in protein precipitation. Biotechnol Bioeng 27:1434-1444.
18. Glatz CE, Hoare M, Landavertiz J. 1986. The formation and growth of protein precipitates in a continuous stirred-tank reactor. AIChE J 32:1196-1204.
19. Grabenbauer GC, Glatz CE. 1981. Protein precipitation-analysis of particle-size distribution and kinetics. Chem Eng Commun 12:203-219.
20. Debenedetti PG. 1996. Metastable liquids: Concepts and principles. Princeton: Princeton University Press. 400p.
21. Gibbs JW. 1875-1876, 1877-1878. On the equilibrium of heterogeneous substances. Trans Conn Acad Sci III 108:343.
22. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, Wypych J, Randolph TW, Narhi LO, Biere AL, Citron M, Carpenter JF. 2003. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42:829-837.
23. Akers MJ. 1984. Considerations in selecting antimicrobial preservatives for parenteral product development. Pharm Technol 8:36-44.
24. Akers MJ. 2001. Proceedings of 2001 IBC Conference on Protein Formulation, San Diego, CA.
25. Akers MJ. 2002. Excipient-drug interactions in parenteral formulations. J Pharm Sci 91:2283-2300.
26. Maa YF, Hsu CC. 1996. Aggregation of recombinant human growth hormone induced by phenolic compounds. Int J Pharm 140:155-168.
27. Fransson J, Hallen D, Florin Robertsson E. 1997. Solvent effects on the solubility and physical stability of human insulin-like growth factor I. Pharm Res 14:606-612.
28. Lam XM, Patapoff TW, Nguyen TH. 1997. The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 14:725-729.
29. Gupta S, Kaisheva E. 2003. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS Pharmsci 5(2): Article #8.
30. Remmele RL, Nightlinger NS, Srinivasan S, Gombotz WR. 1998. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 15:200-208.
31. Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. 2004. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleuki-1 receptor antagonist in aqueous solution. J Pharm Sci 93:3076-3089.
32. Randolph AD, Beckman JR, Kraljevich ZI. 1977. Crystal size distribution dynamics in a classified crystallizer 1. Experimental and theoretical-study of cycling in a potassium-chloride crystallizer. AIChE J 23:500-510.
33. Dong AC, Kendrick B, Kreilgard L, Matsuura J, Manning MC, Carpenter JF. 1997. Spectroscopic study of secondary structure and thermal denaturation of recombinant human factor XIII in aqueous solution. Arch Biochem Biophys 347: 213-220.
34. Schreuder HA, Rondeau JM, Tardif C, Soffientini A, Sarubbi E, Akeson A, Bowlin TL, Yanofsky S, Barrett RW. 1995. Refined crystal-structure of the interleukin-1 receptor antagonist-presence of a disulfide link and a cis-proline. Eur J Biochem 227: 838-847.
35. Jones AG. 2002. Crystallization process systems. edn. Oxford: Butterworth-Heinemann.